Articles tagged with Lung Cancer
Research found skewed X inactivation in women with BRCA1 gene mutations, associated with a later onset of breast or ovarian cancer. The Impact of Cancer scale was also refined and validated, providing a tool to measure long-term psychosocial impact on cancer survivors.
Researchers found that in-home photography may be a cost-effective alternative to professional visual home assessments for identifying asthma triggers. Additionally, health-care utilization for children with asthma peaks in the fall, while tadalafil shows promise as an effective therapy for pulmonary hypertension. In-hospital statin us...
New report finds lung cancer media coverage is on the rise, but with a significant decrease in positive coverage and an overemphasis on smoking as a risk factor. Despite this, breast cancer coverage remains more favorable, often featuring personal stories of survivors.
A study by Stanford Cancer Center found that younger patients (15-39 years) with lung cancer exhibit better survival rates and distinct clinical features compared to older patients. The age-adjusted incidence rate of lung cancer in younger patients was significantly lower, and they had a higher proportion of distant disease at diagnosis.
A collaborative study of nearly 200 lung cancer patients has identified over 1,000 genetic alterations and pinpointed 26 frequently altered genes. The research highlights the importance of integrating multiple large-scale approaches to highlight key molecular defects in lung tumors.
Researchers have discovered 26 new genes linked to lung adenocarcinoma, a type of non-small cell lung cancer. The study's findings suggest that these genetic alterations can be targeted with specific treatments, offering new hope for patients.
A study of 188 patients revealed 26 genes involved in the development of lung adenocarcinoma and its sub-types, including those in non-smokers. The findings could lead to improved diagnosis and treatment options for this deadliest form of lung cancer.
A Harvard T.H. Chan School of Public Health study projects that China will experience an estimated 65 million COPD deaths and 18 million lung cancer deaths between 2003 and 2033 if current smoking and biomass fuel use levels continue, highlighting the need for large-scale interventions to reduce disease burden
A study finds that eliminating smoking and solid fuel use in China could prevent millions of deaths from chronic diseases. Gradual elimination or moderate-aggressive interventions could avoid 26-31 million COPD deaths and 6.3 million lung cancer deaths by 2033.
Scientists identified P-Cadherin as a key molecule in causing colon cancer, with abnormal expression leading to pre-cancerous growths in the bowel. Their findings hold promise for preventative therapies and lifestyle changes to prevent or treat the disease.
A study analyzing English cancer patients found that cervical and lung cancer rates are higher among poor people, while breast and melanoma rates are higher in wealthier groups. Smoking is strongly associated with socioeconomic status and contributes to the higher incidence of lung cancer in deprived groups.
A study of 20 recorded interactions found that physicians rarely responded empathetically to concerns raised by patients with lung cancer. Opportunities for empathy were most often related to the impact of lung cancer on patients' morbidity and mortality expectations, but were frequently overlooked by physicians.
A study published in the Archives of Internal Medicine found that physicians rarely responded empathically to patients' concerns about mortality, symptoms, or treatment options. The researchers identified 384 moments of
In a phase II trial, pazopanib was found to shrink lung cancer tumors in 30 out of 35 patients by up to 85%. The results suggest that pazopanib is highly active in early stage operable lung cancer. Further development of this drug in lung cancer is underway.
Multidisciplinary approaches combining chemotherapy, radiotherapy, and surgery have shown promise in treating various cancers, including lung and head and neck cancers. The addition of targeted therapies like pazopanib and cetuximab has demonstrated significant activity in reducing tumor size and improving patient outcomes.
A new blood test uses immune system signals to detect early signs of lung cancer, signaling the disease before symptoms appear. The test has a sensitivity rate of 51% and specificity rate of 18%, indicating its potential for improving early detection of lung cancer.
A study at ESMO found gefitinib to be more tolerable and result in a greater likelihood of response in non-smoking Asian patients with adenocarcinoma of the lung. The targeted therapy is now considered a first-line treatment for this population.
Researchers found that patients with specific EGFR gene mutations can live almost two years on average when treated with erlotinib, outperforming chemotherapy by two-to-three fold. The study identified a subgroup of 15-22% patients who can benefit from targeted therapies
A narrow genetic region on chromosome 15 has been found to significantly increase the risk of familial lung cancer by 5.7- to 7.2-fold, regardless of smoking status. The study identified specific genetic variants associated with the increased risk and suggests they may be targeted for cancer therapies.
A study adjusting for a known bias in familial melanoma risk estimates reveals an increased relative risk of 3.18, with higher risks for young-onset cases. In contrast, the risks for colorectal, lung, breast, and prostate cancer remain relatively stable.
A study of 2 million people and 22 cancer registries found that African Americans and Asians living outside the US have higher death rates from lung cancer than Europeans. Lung cancer risk among never smokers is not increasing, contradicting previous research.
A new study by the American Cancer Society found that lung cancer death rates among never-smokers are highest among men, African Americans, and Asians in Asia. The review analyzed data from over 630,000 individuals and found that the incidence of lung cancer among lifelong nonsmokers is similar to brain and nervous system cancers.
Researchers have identified African-Americans as having a greater risk of developing lung cancer from chronic obstructive pulmonary disease (COPD), with a more than sixfold increased risk. Hay fever was also found to be protective among African-Americans, reducing the risk by 44%.
Researchers developed a new model specifically for African-American populations, refining lung cancer risk prediction with unique results based on increased exposure to risks. The study also expanded the original Spitz model by adding DNA repair capacity measures, improving predictive capability.
A study published in Journal of Consumer Research found that simply asking people if they're willing to volunteer their time leads to increased donations of both time and money. This effect cannot be explained by guilt or feelings of obligation, suggesting a deeper psychological connection between giving time and experiencing happiness.
A combination of S-1 and irinotecan appears to offer a promising alternative to standard treatment for advanced non-small cell lung cancer, with similar response rates and progression-free survival. The experimental therapy resulted in less severe side effects compared to platinum-based chemotherapy regimens.
A gene expression test could help determine which patients need more aggressive treatment, improving lung cancer survival rates. The study used a large dataset of lung cancer tissue samples to analyze hundreds of genes and predict patient outcomes.
Research suggests that passive smoking poses a significant risk to lung cancer development, with sidestream smoke potentially more carcinogenic than mainstream smoke. The study proposes using DNA-lesion footprinting and mutagenicity analysis to identify unique biological markers for assessing lung cancer risk in relation to SHS exposure.
Research finds that smokeless tobacco products carry a lower cancer risk compared to smoking, particularly for oral and oesophageal cancers. However, users are still at increased risk of other types of cancer, such as lung cancer, especially in countries with high STP use.
Smoke-free policies are reducing heart disease related to smoke exposure, prevalence of smoking in adults, and second-hand smoke exposure. These policies also increase smoke-free environments and have benefits for non-smokers.
A study published in The Lancet Oncology found that radiofrequency ablation can be an effective treatment for small lung tumors, with a confirmed complete response rate of 88% and overall survival rates ranging from 48-75%. The procedure was also shown to have a low risk of complications, including pneumothorax and pleural effusion.
A recent study published in The Lancet Oncology found that smoking does not increase the risk of lung cancer in women compared to men. However, women who have never smoked are at higher risk of developing lung cancer than men who have never smoked.
A new study suggests that CT lung cancer screening can increase lung cancer detection by 37% and reduce mortality by 28%, but has limited impact on all-cause mortality. Quitting smoking is still the most effective way to reduce risk of death from various causes.
A team of researchers from the University of Leeds has made a breakthrough in understanding finger clubbing by identifying its link to lung cancer. The team discovered that a genetic mutation prevents the breakdown of fatty compound PGE2, leading to swollen fingers and fingernails.
UCLA researchers found that smokers who ingested high levels of flavonoids had a lower risk of developing lung cancer. Flavonoids are water-soluble plant pigments with antioxidant and anti-inflammatory properties.
Researchers at the University of Pennsylvania's CEET have discovered that polycyclic aromatic hydrocarbons (PAHs) can lead to mutations in critical genes in lung cancer through oxidative stress. PAHs transform into oxygen free radicals, which bind to DNA and cause damage if not repaired.
A genetic disorder previously associated with lung disease may also increase lung cancer risk, according to a study. Researchers found that carriers of the disorder had a 70-100% increased risk of lung cancer compared to non-carriers.
Research found that individuals with gum disease have an increased risk of various cancers, including lung, kidney, and pancreatic cancers. Gum disease was associated with a 14% higher overall cancer risk compared to those without gum disease.
Researchers found that carrying alpha-1 antitrypsin deficiency increases lung cancer risk in smokers and nonsmokers, with the genetic disorder explaining up to 12% of lung cancer patients. Individuals who carry the gene should be screened for lung cancer and avoid potential carcinogens.
Researchers developed a blood test that can detect lung cancer in its earliest stages with high accuracy, potentially eliminating the need for invasive biopsies. The test uses gene expression analysis of circulating white blood cells and showed an 87% accuracy rate.
A first-of-its-kind lung cancer chemoprevention trial found Celebrex reduces precancerous lesion proliferation and is safe for high-risk individuals. The study demonstrated the importance of COX-2 inhibition in preventing lung cancer, with potential implications for cancer prevention and treatment.
A new study led by Duke University researchers found that lung cancer patients can tolerate exercise after surgery, leading to improved tolerance for physical activity and better overall quality of life. The 14-week study showed significant gains in aerobic fitness and reduced fatigue among participants.,
Researchers pinpointed the protein FANCD2 as slowed production leads to genetic changes triggering lung cancer. Low levels of FANCD2 cause DNA damage and faulty cells committing suicide.
Women who quit smoking experience a significant reduction in mortality risk, with 61% of the benefit realized within 5 years for coronary heart disease and 42% for cerebrovascular mortality. Quitting also reduces lung cancer mortality risk by 21% within 5 years, with an 87% reduction after 20-30 years.
A new study published in the Journal of the National Cancer Institute estimates that Medicare costs for elderly cancer patients will top $21.1 billion over a 5-year period. The estimated cost varies widely depending on tumor type, stage at diagnosis, and phase of care.
A new clinical trial found that MAGE-A3 ASCI reduces the risk of lung cancer relapse after surgery, similar to chemotherapy but with fewer side effects. The treatment, which boosts the immune system, showed minimal reactions at injection sites and was suitable for long-term maintenance treatment.
Research suggests common viruses, such as human papillomavirus (HPV) and measles virus, may play a role in lung cancer development, particularly in smokers. Studies have found that five out of 22 non-small-cell lung cancer samples were positive for HPV.
A new online database provides a comprehensive list of somatic EGFR mutations, allowing clinicians to make more robust decisions about treatment options for non-small-cell lung cancer patients. The database includes data from thousands of patients and offers improved treatment outcomes for those receiving tyrosine kinase inhibitors.
A study at the University of Texas M. D. Anderson Cancer Center found that oral tissue can be used to monitor molecular events in less accessible lung tissue. The research discovered that cells lining the mouth reflect the same antitumor genes silenced in oral and lung tissue, offering a new approach to detecting lung cancer.
Researchers found that nicotine increases osteopontin production, promoting cancer cell survival and spread. Elevated osteopontin levels have been detected in pancreatic cancer patients, suggesting a potential role in the cigarette smoking-pancreatic cancer connection.
A large-scale study has found a specific gene variant that increases the risk of lung cancer. The researchers also discovered a connection between this gene and nicotine dependence, as well as smoking behavior.
A recent study has identified two common genetic variants associated with an increased risk of lung cancer in smokers and former smokers. The variants, present in about half of the Caucasian population, were found to increase the risk by 28-81%.
Researchers at Boston University School of Medicine have developed a clinicogenomic model to test for lung cancer with increased sensitivity and specificity. The model combines gene expression and clinical risk factors, offering improved accuracy in identifying patients who would benefit from further invasive testing.
A new study published in Health Physics found that exposure to low levels of radon gas may reduce the risk of developing lung cancer, with a 60% reduction observed at certain levels. The study involved nearly 600 Massachusetts homes and adjusted for factors such as smoking and education.
Researchers at Yale University and Asuragen, Inc. found that the microRNA let-7 substantially reduced cancer growth in multiple mouse models of lung cancer, indicating a direct role for miRNAs in cancer progression. The study introduces a new paradigm for using miRNAs as effective therapeutic agents to treat human cancer.
Two researchers, Hildegard Schuller and Albert Baldwin, received funding for studies on sex differences in lung cancer and the regulation of normal cell growth. The grants aim to increase understanding of lung cancer and support scientists pursuing lung cancer research.
Dr. Adam Marcus receives $80,000 award to study lung cancer cell invasion and mutations of the LKB1 protein. This research could lead to novel diagnostic and prognostic approaches to control lung cancer malignancy.
Scientists have discovered specific methylation patterns in tumors and tissue that can predict which lung cancers are more likely to recur. These patterns could lead to reclassifying small lung cancers as advanced disease, allowing for more aggressive treatment options.
AstraZeneca's investigational cancer drug vandetanib has completed patient enrollment in two pivotal Phase III studies for the second-line treatment of non-small cell lung cancer. The ZODIAC and ZEAL studies aim to assess the efficacy of vandetanib in combination with chemotherapy treatments.
A study published by the American Thoracic Society found that certain vitamin supplements, including multivitits, vitamin C, and folate, did not protect against lung cancer and may even increase the risk. The risk was highest among current smokers, with a seven percent rise in risk for every 100mg/day of supplemental vitamin E.